NASDAQ:ITUS ITUS (ITUS) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free ITUS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$4.61▼$4.7650-Day Range N/A52-Week Range$1.83▼$6.43Volume69,859 shsAverage Volume134,373 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ITUS alerts: Email Address Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> About ITUS Stock (NASDAQ:ITUS)Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body's immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immune-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.Read More Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> ITUS Stock News HeadlinesMarch 27, 2024 | msn.comMan arrested in Titus County sex sting operationMarch 23, 2024 | nasdaq.comMay 3rd Options Now Available For Eli Lilly (LLY)March 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 18, 2024 | msn.comSome bay clouds Monday with sunny and warm afternoonMarch 17, 2024 | msn.comSunny skies for your SundayMarch 11, 2024 | msn.com"A kit with some surprising tricks up its sleeve": Donner Backbeat reviewMarch 9, 2024 | msn.comFactChecking Biden’s State of the UnionMarch 7, 2024 | msn.comSeven candidates for three seats on 5th District Court of Appeals, in all-GOP affairMarch 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.February 21, 2024 | msn.comITU's AI for Good Global Summit 2024 puts tech to the test for people and planetFebruary 19, 2024 | msn.comChapel Hill ISD announces $9.3 million bond election for MayFebruary 13, 2024 | msn.comUS Senate Passes Ukraine Aid Bill, House Likely To Reject ItFebruary 6, 2024 | ft.comLetter: One way to raise quality of classroom discussionsJanuary 26, 2024 | msn.comSeasonably cool Thursday with sunshineJanuary 14, 2024 | msn.com‘Your Tahoe needs a tune up buddy’: Man who taunted police after escaping dangerous chase busted by his own Snapchat braggingJanuary 13, 2024 | msn.com'Your Tahoe needs a tune up buddy': Man who taunted police after escaping dangerous chase busted by his own Snapchat braggingJanuary 10, 2024 | theglobeandmail.comItus Mouthguardz Earns Global Acclaim for USA Patented Anti-Snore DeviceJanuary 10, 2024 | msn.comScattered showers for your WednesdayJanuary 8, 2024 | msn.comOpinion: Maybe it’s time for me to just accept my geezerhood?December 24, 2023 | msn.comChilly weather for the holidaysDecember 18, 2023 | msn.comNdieze Lagos Warn Against Indiscriminate Conferment Of Chieftaincy TitlesDecember 12, 2023 | msn.comSunny Tuesday with seasonable tempsDecember 10, 2023 | uk.news.yahoo.comWhat is norovirus, how do you prevent it, and are cases rising?December 5, 2023 | usnews.comUS Makes Offer to Bring Home Jailed Americans Paul Whelan and Evan Gershkovich. Russia Rejected ItDecember 5, 2023 | msn.comMostly clear and sunny TuesdayNovember 30, 2023 | msn.comGMFS CASA Charity Lunch!November 30, 2023 | msn.comCristiano Ronaldo faces $1B class-action lawsuit for promoting for Binance NFTsSee More Headlines Receive ITUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ITUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/09/2018Today3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Patent Owners & Lessors Sub-IndustryN/A Current SymbolNASDAQ:ITUS CUSIPN/A CIK715446 Webwww.ituscorp.com Phone(408) 708-9808FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesAmit D. KumarExecutive Chairman, President & CEOMichael J. CatelaniSecretary, Chief Operating & Financial OfficerThomas SchlumpbergerExecutive Vice President-DiagnosticsKey CompetitorsEqonexNASDAQ:EQOSFull Truck AllianceNYSE:YMMFutuNASDAQ:FUTUIntegrated Media TechnologyNASDAQ:IMTEOnion GlobalNYSE:OGBLYView All Competitors ITUS Stock Analysis - Frequently Asked Questions How were ITUS's earnings last quarter? ITUS Co. (NASDAQ:ITUS) released its quarterly earnings results on Friday, March, 9th. The business services provider reported ($0.11) EPS for the quarter. What other stocks do shareholders of ITUS own? Based on aggregate information from My MarketBeat watchlists, some companies that other ITUS investors own include Synergy Pharmaceuticals (SGYP), Galectin Therapeutics (GALT), Progenics Pharmaceuticals (PGNX), Catalyst Pharmaceuticals (CPRX), Halozyme Therapeutics (HALO), Palatin Technologies (PTN), Advanced Micro Devices (AMD), Coherus BioSciences (CHRS) and CME Group (CME). This page (NASDAQ:ITUS) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the MarketsMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ITUS Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.